MedTrace Logo

grouP O wholE blooD : storagE leSion impacT And infLammation

NCT06809010 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-06

No results posted yet for this study

Summary

"Etablissement Français du Sang" (EFS) prepares labile blood products from blood donations that are separated by type (red blood cells, plasma and platelets).

The "Centre de Transfusion Sanguine des Armées" (CTSA) produces an innovative labile blood product, LTO-WB, corresponding to group O leukocyte-free whole blood.

The objective of the PEDESTAL EFS study is to compare the inflammatory and biological characteristics of blood products prepared by the EFS vs. the labile blood product prepared by the CTSA.

Conditions

  • Blood Donation
  • Blood Platelets
  • Blood Donors
  • Inflammation
  • Transfusion

Interventions

BIOLOGICAL

Whole blood donation

This intervention involves the collection of a whole blood bag.

BIOLOGICAL

Apheresis donation

This procedure involves the collection of a plasma/platelets bag by apheresis

Sponsors & Collaborators

  • Centre de transfusion sanguine des Armées, Clamart, France

    collaborator UNKNOWN

  • INSERM, SAINBIOSE U1059

    collaborator UNKNOWN

  • Etablissement Français du Sang

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-12
Primary Completion
2028-02-29
Completion
2028-02-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06809010 on ClinicalTrials.gov